GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance

Biochemical Pharmacology

Volumn 83, Issue 12, 2012, Pages 1613-1622

  Sodani, Kamlesh ^a   Tiwari, Amit K ^a   Singh, Satyakam ^a   Patel, Atish ^a   Xiao, Zhi Jie ^a   Chen, Jun Jiang ^a   Sun, Yue Li ^a   Talele, Tanaji T ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

ABCB1; ABCG2; GW2974; GW583340; Multidrug resistance; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; COLCHICINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GW 2974; GW 583340; LAPATINIB; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MEMBRANE VESICLE; MOLECULAR DOCKING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STRUCTURAL HOMOLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; NEOPLASM PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SULFONES;

EID: 84860162685     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.02.028     Document Type: Article

References (51)

1. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 2002 48 58
2. V. Vasiliou, K. Vasiliou, and D.W. Nebert Human ATP-binding cassette (ABC) transporter family Hum Genomics 3 2009 281 290
3. M. Dean, and T. Annilo Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates Annu Rev Genomics Hum Genet 6 2005 123 142
4. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res 11 2001 1156 1166
5. M.M. Gottesman, Ambudkar, and S.V. Overview ABC transporters and human disease J Bioenerg Biomembr 33 2001 453 458
6. L.J. Goldstein, M.M. Gottesman, and I. Pastan Expression of the MDR1 gene in human cancers Cancer Treat Res 57 1991 101 119
7. G.D. Kruh, and M.G. Belinsky The MRP family of drug efflux pumps Oncogene 22 2003 7537 7552
8. L.A. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358
9. P. Krishnamurthy, and J.D. Schuetz Role of ABCG2/BCRP in biology and medicine Annu Rev Pharmacol Toxicol 46 2006 381 410
10. J.F. Flynn, C. Wong, and J.M. Wu Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer J Oncol 2009 2009 526963
11. N. Normanno, L.A. De, C. Bianco, L. Strizzi, M. Mancino, and M.R. Maiello Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2006 2 16
12. K.E. Lackey Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor Curr Top Med Chem 6 2006 435 460
13. C. Erlichman, S.A. Boerner, C.G. Hallgren, R. Spieker, X.Y. Wang, and C.D. James The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res 61 2001 739 748
14. T. Kitazaki, M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, and M. Yasunaga Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer 49 2005 337 343
15. K. Yanase, S. Tsukahara, S. Asada, E. Ishikawa, Y. Imai, and Y. Sugimoto Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol Cancer Ther 3 2004 1119 1125
16. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, and R.W. Robey Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 2007 11012 11020
17. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, I.W. Kim, and S. Parmar Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478 Biochem Pharmacol 77 2009 781 793
18. A.K. Tiwari, K. Sodani, S.R. Wang, Y.H. Kuang, C.R. Ashby Jr., and X. Chen Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters Biochem Pharmacol 78 2009 153 161
19. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, and D.G. Liu Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 2008 7905 7914
20. S.R. Johnston, and A. Leary Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer Drugs Today (Barc) 42 2006 441 453
21. L.S. Schwartzberg, S.X. Franco, A. Florance, L. O'Rourke, J. Maltzman, and S. Johnston Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer Oncologist 15 2010 122 129
22. K.M. Aird, X. Ding, A. Baras, J. Wei, M.A. Morse, and T. Clay Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Mol Cancer Ther 7 2008 38 47
23. K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, and J. Digiovanni Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma Clin Cancer Res 11 2005 5572 5580
24. L.M. Witters, A. Witkoski, M.D. Planas-Silva, M. Berger, J. Viallet, and A. Lipton Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor Oncol Rep 17 2007 465 469
25. N.L. Spector, Y. Yarden, B. Smith, L. Lyass, P. Trusk, and K. Pry Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells Proc Natl Acad Sci USA 104 2007 10607 10612
26. S. Nagayama, Z.S. Chen, M. Kitazono, Y. Takebayashi, K. Niwa, and K. Yamada Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078 Cancer Lett 130 1998 175 182
27. S. Akiyama, A. Fojo, J.A. Hanover, I. Pastan, and M.M. Gottesman Isolation and genetic characterization of human KB cell lines resistant to multiple drugs Somat Cell Mol Genet 11 1985 117 126
28. R.W. Robey, Y. Honjo, K. Morisaki, T.A. Nadjem, S. Runge, and M. Risbood Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br J Cancer 89 2003 1971 1978
29. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res 47 1987 936 942
30. Z.S. Chen, R.W. Robey, M.G. Belinsky, I. Shchaveleva, X.Q. Ren, and Y. Sugimoto Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport Cancer Res 63 2003 4048 4054
31. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, and R. Zhuo Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 323 2009 1718 1722
32. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, S. Singh, and I.W. Kim Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Cancer Res 71 2011 3029 3041
33. M.F. Rosenberg, Z. Bikadi, J. Chan, X. Liu, Z. Ni, and X. Cai The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone Structure 18 2010 482 493
34. E. Hazai, and Z. Bikadi Homology modeling of breast cancer resistance protein (ABCG2) J Struct Biol 162 2008 63 74
35. Q. Mao, and J.D. Unadkat Role of the breast cancer resistance protein (ABCG2) in drug transport AAPS J 7 2005 E118 E133
36. H. Mitomo, R. Kato, A. Ito, S. Kasamatsu, Y. Ikegami, and I. Kii A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport Biochem J 373 2003 767 774
37. M. Miwa, S. Tsukahara, E. Ishikawa, S. Asada, Y. Imai, and Y. Sugimoto Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants Int J Cancer 107 2003 757 763
38. O. Alqawi, S. Bates, and E. Georges Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding Biochem J 382 2004 711 716
39. Z. Ni, Z. Bikadi, X. Cai, M.F. Rosenberg, and Q. Mao Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport Am J Physiol Cell Physiol 299 2010 C1100 C1109
40. D.W. Rusnak, K. Affleck, S.G. Cockerill, C. Stubberfield, R. Harris, and M. Page The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res 61 2001 7196 7203
41. S. Cockerill, C. Stubberfield, J. Stables, M. Carter, S. Guntrip, and K. Smith Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2 Bioorg Med Chem Lett 11 2001 1401 1405
42. N.B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, and O. Ujhelly Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) Cancer Res 65 2005 1770 1777
43. R.S. Midgley, D.J. Kerr, K.T. Flaherty, J.P. Stevenson, S.E. Pratap, and K.M. Koch A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan Ann Oncol 18 2007 2025 2029
44. H.A. Burris III, H.I. Hurwitz, E.C. Dees, A. Dowlati, K.L. Blackwell, and B. O'Neil Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 2005 5305 5313
45. A.K. Bence, E.B. Anderson, M.A. Halepota, M.A. Doukas, P.A. DeSimone, and G.A. Davis Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects Invest New Drugs 23 2005 39 49
46. E. Nicolle, A. Boumendjel, S. Macalou, E. Genoux, A. hmed-Belkacem, and P.A. Carrupt QSAR analysis and molecular modeling of ABCG2-specific inhibitors Adv Drug Deliv Rev 61 2009 34 46
47. G.F. Ecker, and P. Chiba Transporters as drug carriers 2009 Wiley-VCH
48. G. Klopman, L.M. Shi, and A. Ramu Quantitative structure-activity relationship of multidrug resistance reversal agents Mol Pharmacol 52 1997 323 334
49. P. Crivori, B. Reinach, D. Pezzetta, and I. Poggesi Computational models for identifying potential P-glycoprotein substrates and inhibitors Mol Pharm 3 2006 33 44
50. I.K. Pajeva, C. Globisch, and M. Wiese Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors ChemMedChem 4 2009 1883 1896
51. Z. Parveen, T. Stockner, C. Bentele, S. Pferschy, M. Kraupp, and M. Freissmuth Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein Mol Pharmacol 79 2011 443 452